Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

Wegovy: sales of weight loss injection more than double - The company said more than 45 million people were now ‘benefitting ...

In a 72-week study, Zepbound's mean weight loss was 20.2%, while Wegovy's was 13.7%. Amycretin did better in half the time. Novo Nordisk faces at least two issues in the anti-obesity space.

More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and other brands if they are struggling with obesity or have a health ...

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

Hagman said doctors might want to consider prescribing GLP-1 weight loss drugs like Wegovy and Zepbound to children with obesity, based on these results. Those drugs are rarely used in children.

"Wegovy is for those dealing with obesity and weight-related problems, not for people who just want to lose some weight." Wegovy is taken via an injection once a week. Should you meet the eligibility ...

When it comes to ages 12 to 18 who are dealing with obesity, Americans are divided: About one-third say the use of weight-loss drugs in this context is a “very” or “somewhat” good thing, a ...